Javascript must be enabled to continue!
CYP3A Genotypes in Bangladeshi Tuberculosis Patients
View through CrossRef
The purpose of this study is to investigate the genotype and allelic frequencies of CYP3A in Bangladeshi Tuberculosis (TB) patients which may help for individualized drug dosing and improved therapeutics. Genotyping was done using the extracted genomic DNA from 90 TB patients followed by amplification of target alleles by PCR. Amplified alleles were then digested by restriction enzymes followed by gel electrophoresis & sequencing to identify the targeted alleles namely CYP3A4*1B, CYP3A4*2, CYP3A4*4, CY3A4*5, CYP3A4*6, CYP3A4*10, CYP3A4*18, and CYP3A5*3. In TB patients, no samples were positive for CYP3A4*2, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*10, and CYP3A4*18 alleles. One sample was found to be heterozygous for CYP3A4*1B (1.11%). The wild homozygous (CYP3A5*1/*1) genotype frequency was 7.78%, the heterozygous (CYP3A5*1/*3) frequency was 42.22% and the homozygous mutant (CYP3A5*3/*3) frequency was 50% in Bangladeshi TB patients. The absence of the common polymorphic gene suggests that there will be no impact of CYP3A drug metabolizing enzymes on antituberculosis drugs.DOI: http://dx.doi.org/10.3329/bmrcb.v38i1.6978Bangladesh Med Res Counc Bull 2012; 38: 1-5
Bangladesh Academy of Sciences
Title: CYP3A Genotypes in Bangladeshi Tuberculosis Patients
Description:
The purpose of this study is to investigate the genotype and allelic frequencies of CYP3A in Bangladeshi Tuberculosis (TB) patients which may help for individualized drug dosing and improved therapeutics.
Genotyping was done using the extracted genomic DNA from 90 TB patients followed by amplification of target alleles by PCR.
Amplified alleles were then digested by restriction enzymes followed by gel electrophoresis & sequencing to identify the targeted alleles namely CYP3A4*1B, CYP3A4*2, CYP3A4*4, CY3A4*5, CYP3A4*6, CYP3A4*10, CYP3A4*18, and CYP3A5*3.
In TB patients, no samples were positive for CYP3A4*2, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*10, and CYP3A4*18 alleles.
One sample was found to be heterozygous for CYP3A4*1B (1.
11%).
The wild homozygous (CYP3A5*1/*1) genotype frequency was 7.
78%, the heterozygous (CYP3A5*1/*3) frequency was 42.
22% and the homozygous mutant (CYP3A5*3/*3) frequency was 50% in Bangladeshi TB patients.
The absence of the common polymorphic gene suggests that there will be no impact of CYP3A drug metabolizing enzymes on antituberculosis drugs.
DOI: http://dx.
doi.
org/10.
3329/bmrcb.
v38i1.
6978Bangladesh Med Res Counc Bull 2012; 38: 1-5.
Related Results
Abstract 3016: Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers
Abstract 3016: Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers
Abstract
Background: Tucatinib is a potent, highly selective HER2 tyrosine kinase inhibitor in development for the treatment of patients with HER2+ metastatic breast...
Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
AbstractMilademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including li...
Studying cases of extrapulmonary tuberculosis in the National Center for Tuberculosis Control in Damascus
Studying cases of extrapulmonary tuberculosis in the National Center for Tuberculosis Control in Damascus
Abstract
Background :Tuberculosis (TB) is a major public health concern worldwide and is the 13th leading cause of death and the second deadliest infectious disease after C...
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
<p dir="ltr">Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis), remains a leading global health concern, responsible for millions of inf...
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
<p dir="ltr">Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis), remains a leading global health concern, responsible for millions of inf...
Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model
Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model
AbstractThalidomide is a teratogen in humans but not in rodents. It causes multiple birth defects including malformations of limbs, ears, and other organs. However, the species-spe...
Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio
Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio
Changes in cortisol and other hormones during pregnancy may alter CYP3A enzymes activity, but data from sub-Saharan Africa are sparse. We investigated the effect of pregnancy and C...
Trend of pulmonary tuberculosis and rifampicin-resistance among tuberculosis presumptive patients in Central Tigray, Ethiopia; 2018 -2023: a six-year retrospective study
Trend of pulmonary tuberculosis and rifampicin-resistance among tuberculosis presumptive patients in Central Tigray, Ethiopia; 2018 -2023: a six-year retrospective study
Abstract
Background
Tuberculosis (TB) is a major public health concern in the developing countries. Moreover, the emergence of multidrug-resistant t...

